ENHO gene therapy using Adropin for heart failure

University of Pittsburgh-Central Development filed USPTO Patent Application US20260091136A1 covering methods for preventing and treating cardiometabolic diseases through gene therapy that provides endogenous production of Adropin (encoded by the ENHO gene). The application specifically targets heart failure with preserved ejection fraction (HFpEF). CPC classifications indicate focus on gene therapy vectors (A61K 48/005, C12N 15/86) and cardiovascular therapeutics (A61P 9/04).

This is a patent application publication rather than a regulatory requirement. No compliance deadlines, required actions, or penalties apply. Entities in the pharmaceutical and biotechnology sectors developing gene therapies for cardiometabolic conditions may wish to review this application to assess potential freedom-to-operate implications for competing therapeutic approaches.